These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32697437)

  • 41. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.
    Andersen JT; Dalhus B; Viuff D; Ravn BT; Gunnarsen KS; Plumridge A; Bunting K; Antunes F; Williamson R; Athwal S; Allan E; Evans L; Bjørås M; Kjærulff S; Sleep D; Sandlie I; Cameron J
    J Biol Chem; 2014 May; 289(19):13492-502. PubMed ID: 24652290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Charge Variant of Bevacizumab Offers Enhanced FcRn-Dependent Pharmacokinetic Half-Life and Efficacy.
    Singh SK; Kumar D; Nagpal S; Dubey SK; Rathore AS
    Pharm Res; 2022 May; 39(5):851-865. PubMed ID: 35355206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
    Dall'Acqua WF; Kiener PA; Wu H
    J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies.
    Bryniarski MA; Tuhin MTH; Acker TM; Wakefield DL; Sethaputra PG; Cook KD; Soto M; Ponce M; Primack R; Jagarapu A; LaGory EL; Conner KP
    J Pharm Sci; 2024 Sep; 113(9):2879-2894. PubMed ID: 38906252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoclonal antibodies directed against human FcRn and their applications.
    Christianson GJ; Sun VZ; Akilesh S; Pesavento E; Proetzel G; Roopenian DC
    MAbs; 2012; 4(2):208-16. PubMed ID: 22453095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Target-independent variable region mediated effects on antibody clearance can be FcRn independent.
    Kelly RL; Yu Y; Sun T; Caffry I; Lynaugh H; Brown M; Jain T; Xu Y; Wittrup KD
    MAbs; 2016 Oct; 8(7):1269-1275. PubMed ID: 27610650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced elimination of IgG antibodies by engineering the variable region.
    Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
    Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys.
    Li T; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):701-713. PubMed ID: 30423340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
    Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
    Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance.
    Goulet DR; Watson MJ; Tam SH; Zwolak A; Chiu ML; Atkins WM; Nath A
    Drug Metab Dispos; 2018 Dec; 46(12):1900-1907. PubMed ID: 30232177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.
    Igawa T; Maeda A; Haraya K; Tachibana T; Iwayanagi Y; Mimoto F; Higuchi Y; Ishii S; Tamba S; Hironiwa N; Nagano K; Wakabayashi T; Tsunoda H; Hattori K
    PLoS One; 2013; 8(5):e63236. PubMed ID: 23667591
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.
    Sheridan D; Yu ZX; Zhang Y; Patel R; Sun F; Lasaro MA; Bouchard K; Andrien B; Marozsan A; Wang Y; Tamburini P
    PLoS One; 2018; 13(4):e0195909. PubMed ID: 29649283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
    Li L; Wu Z; Wu M; Qiu X; Wu Y; Kuang Z; Wang L; Sun T; Liu Y; Yi S; Jing H; Zhou S; Chen B; Wu D; Wu W; Liu J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107008. PubMed ID: 33069927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.
    Richter WF; Christianson GJ; Frances N; Grimm HP; Proetzel G; Roopenian DC
    MAbs; 2018 Jul; 10(5):803-813. PubMed ID: 29621428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.
    Sampei Z; Haraya K; Tachibana T; Fukuzawa T; Shida-Kawazoe M; Gan SW; Shimizu Y; Ruike Y; Feng S; Kuramochi T; Muraoka M; Kitazawa T; Kawabe Y; Igawa T; Hattori K; Nezu J
    PLoS One; 2018; 13(12):e0209509. PubMed ID: 30592762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
    Ferl GZ; Wu AM; DiStefano JJ
    Ann Biomed Eng; 2005 Nov; 33(11):1640-52. PubMed ID: 16341929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS.
    Fan YY; Neubert H
    Anal Chem; 2016 Apr; 88(8):4239-47. PubMed ID: 27012525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.